Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.
Pharming Group to participate in May investor conference
Conference attendancePharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of May:
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
Financial updatesTHIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE IMMEDIATELY FROM THEIR STOCKBROKER, SOLICITOR, ACCOUNTANT OR OTHER INDEPENDENT FINANCIAL OR LEGAL ADVISER. THIS NOTICE IS NOT FOR DISTRIBUTION IN OR TO ANY PERSON LOCATED IN ANY JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
Pharming Group reports first quarter 2024 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the three months ended March 31, 2024.
Pharming Group to report first quarter 2024 financial results on May 8
Financial updatesPharming Group N.V. confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024.
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
Other updatesPharming Group N.V. is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024.
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
Financial updatesPharming Group N.V. announces the final results of its invitation to Eligible Bondholders (as defined below) of the outstanding €125 million 3.00% senior unsecured convertible bonds due 2025 issued on 21 January 2020 (the “2025 Bonds”; ISIN: XS2105716554) to tender for purchase via a reverse bookbuilding process for cash any and all of their 2025 Bonds (the “Invitation”).
Pharming Group announces the placement of €100 million convertible bonds due 2029
Financial updatesPharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces today the placement of €100 million of senior unsecured convertible bonds due 2029 (the “New Bonds”) convertible into new and/or existing ordinary shares in the capital of the Company (the "Shares"). The offer was fully subscribed. The New Bonds were offered via an accelerated book building process through a private placement only to institutional investors outside the United States of America, Australia, Canada, Japan and South Africa.
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
Financial updatesNOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
Clinical trialsThis multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency.